---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-26-000047"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2026-04-23T23:59:59+00:00"
generated_at: "2026-05-15T04:24:15.505556+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q1 beats: revenue up 21%, adj. EPS up 47%; raises FY26 guidance

## Summary
- Net sales of $844.9M (+21% reported, +15.3% organic); GAAP EPS $1.92 (+56%), adjusted EPS $2.13 (+47%)
- High-Value Components revenue $409.3M (+29.6%); HVP Delivery Devices $123.6M (+29.0%); West Vantage $150.6M (+11.6%)
- Raised FY26 net sales guidance to $3.295-3.350B (prev $3.215-3.275B) and adj. EPS to $8.40-8.75 (prev $7.85-8.20)
- Repurchased 1.2M shares for $297.6M at avg $243.57/share under February 2026 buyback program
- Q2 2026 guidance introduced: net sales $830-850M, adj. EPS $2.05-2.12; SmartDose sale to AbbVie expected mid-year

## SEC filing metadata
- accession: 0000105770-26-000047
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2026-04-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/0000105770-26-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/wst-20260423.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-26-000047
- JSON: https://secwatch.observer/filing/0000105770-26-000047.json
- Plain text: https://secwatch.observer/filing/0000105770-26-000047.txt

## Key facts
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported the first quarter of 2026 results: revenue $844.9 million, EPS $1.92. Guidance raised.
  - Period: the first quarter of 2026
  - Revenue: $844.9 million
  - EPS: $1.92
  - Guidance: raised
  - Result: reported results
  source text: West Reports First-Quarter 2026 Results – Strong Start to the Year and Raising Full Year Revenue and EPS guidance Exton, PA, April 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026. First-Quarter Summary (comparisons to prior-year period) • Net sales of $844.9 million increased 21.0%; organic growth was 15.3%. • Diluted earnings per share ("EPS") of $1.92 increased 56.1%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/0000105770-26-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.